MARKET

APLM

APLM

APOLLOMICS INC
NASDAQ
17.26
-0.37
-2.07%
After Hours: 17.04 -0.23 -1.30% 16:10 03/27 EDT
OPEN
18.34
PREV CLOSE
17.63
HIGH
18.36
LOW
17.26
VOLUME
4.47K
TURNOVER
--
52 WEEK HIGH
42.12
52 WEEK LOW
3.659
MARKET CAP
37.06M
P/E (TTM)
-1.5188
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at APLM last week (0316-0320)?
Weekly Report · 5d ago
Apollomics Inc. CEO and Director Chen Hung-Wen filed an initial beneficial ownership statement
Reuters · 03/19 18:03
Apollomics Inc. files Form 3 initial beneficial ownership statement for Director Chen Hong-Jung
Reuters · 03/18 22:53
Apollomics Inc. director Huang Ya-Chi files initial beneficial ownership statement
Reuters · 03/18 22:46
Apollomics Inc. files initial beneficial ownership statement for Director Chu Yi-An
Reuters · 03/18 22:46
Apollomics Inc. files initial beneficial ownership statement for director Hsien-Shu Tsai
Reuters · 03/18 22:44
Apollomics Inc. Director Jan Chen-Huan Files Initial Beneficial Ownership Statement
Reuters · 03/18 22:43
Apollomics Inc. files Form 3 initial beneficial ownership statement for COO and director Yi-Kuei Chen
Reuters · 03/18 22:33
More
About APLM
Apollomics Inc. is a clinical-stage biopharmaceutical company focusing on discovering and developing oncology therapies to address unmet medical needs, especially for difficult-to-treat and treatment-resistant cancers. The product candidates in its pipeline are categorized into two groups based on their mechanisms of action, each of which contains product candidates at different stages of development: tumor inhibitors and immuno-oncology drugs. Its tumor inhibitor product candidates consist of three small-molecule inhibitors against different uncontrolled growth signaling pathways in cancer cells: vebreltinib, APL-102 and APL-122. Its three immuno-oncology product candidates consist of APL-501, APL-502 and APL-80. Vebreltinib is a potent, oral active selective c-Met inhibitor. APL-102 is an oral active, small molecule Multiple Tyrosine Kinase Inhibitor. APL-122 is a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathways. APL-501 is an anti-PD-1 antibody product candidate.

Webull offers Apollomics Inc stock information, including NASDAQ: APLM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APLM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APLM stock methods without spending real money on the virtual paper trading platform.